AU2013308907B2 - Anti-prolactin receptor antibody formulations - Google Patents

Anti-prolactin receptor antibody formulations Download PDF

Info

Publication number
AU2013308907B2
AU2013308907B2 AU2013308907A AU2013308907A AU2013308907B2 AU 2013308907 B2 AU2013308907 B2 AU 2013308907B2 AU 2013308907 A AU2013308907 A AU 2013308907A AU 2013308907 A AU2013308907 A AU 2013308907A AU 2013308907 B2 AU2013308907 B2 AU 2013308907B2
Authority
AU
Australia
Prior art keywords
ser
gly
leu
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013308907A
Other languages
English (en)
Other versions
AU2013308907A1 (en
Inventor
Xinghang Ma
Jianjie NIU
Jun Xiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of AU2013308907A1 publication Critical patent/AU2013308907A1/en
Application granted granted Critical
Publication of AU2013308907B2 publication Critical patent/AU2013308907B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013308907A 2012-08-31 2013-08-28 Anti-prolactin receptor antibody formulations Active AU2013308907B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261695949P 2012-08-31 2012-08-31
US61/695,949 2012-08-31
US13/842,906 2013-03-15
US13/842,906 US8883979B2 (en) 2012-08-31 2013-03-15 Anti-prolactin receptor antibody formulations
PCT/US2013/056976 WO2014036076A1 (en) 2012-08-31 2013-08-28 Anti-prolactin receptor antibody formulations

Publications (2)

Publication Number Publication Date
AU2013308907A1 AU2013308907A1 (en) 2015-03-12
AU2013308907B2 true AU2013308907B2 (en) 2018-04-19

Family

ID=49162240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013308907A Active AU2013308907B2 (en) 2012-08-31 2013-08-28 Anti-prolactin receptor antibody formulations

Country Status (29)

Country Link
US (4) US8883979B2 (cg-RX-API-DMAC7.html)
EP (1) EP2890397B1 (cg-RX-API-DMAC7.html)
JP (1) JP6444871B2 (cg-RX-API-DMAC7.html)
KR (1) KR102100282B1 (cg-RX-API-DMAC7.html)
CN (3) CN111202844A (cg-RX-API-DMAC7.html)
AR (2) AR092387A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013308907B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015004397B1 (cg-RX-API-DMAC7.html)
CA (1) CA2883097C (cg-RX-API-DMAC7.html)
CY (1) CY1121990T1 (cg-RX-API-DMAC7.html)
DK (1) DK2890397T3 (cg-RX-API-DMAC7.html)
ES (1) ES2742868T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191199T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045494T2 (cg-RX-API-DMAC7.html)
IL (1) IL237277B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN02255A (cg-RX-API-DMAC7.html)
LT (1) LT2890397T (cg-RX-API-DMAC7.html)
MX (1) MX367691B (cg-RX-API-DMAC7.html)
NZ (1) NZ705178A (cg-RX-API-DMAC7.html)
PL (1) PL2890397T3 (cg-RX-API-DMAC7.html)
PT (1) PT2890397T (cg-RX-API-DMAC7.html)
RS (1) RS59207B1 (cg-RX-API-DMAC7.html)
RU (1) RU2649372C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201501225SA (cg-RX-API-DMAC7.html)
SI (1) SI2890397T1 (cg-RX-API-DMAC7.html)
TW (3) TW201422235A (cg-RX-API-DMAC7.html)
UY (2) UY34994A (cg-RX-API-DMAC7.html)
WO (1) WO2014036076A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201501279B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302664B (zh) 2012-03-14 2021-11-26 瑞泽恩制药公司 多特异性抗原结合分子及其用途
DK2935331T3 (en) 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
US20160002342A1 (en) * 2013-03-15 2016-01-07 Xinghang Ma Anti-prolactin receptor antibody formulations
NZ753995A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6784683B2 (ja) * 2015-02-09 2020-11-11 ユーシービー バイオファルマ エスアールエル 医薬製剤
NZ737726A (en) 2015-07-06 2023-03-31 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
HUE061985T2 (hu) 2015-08-19 2023-09-28 Astrazeneca Ab Stabil IFNAR1-elleni készítmény
WO2017057644A1 (ja) * 2015-09-30 2017-04-06 持田製薬株式会社 高濃度抗体含有液体製剤
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN116327963A (zh) * 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
IL266917B2 (en) 2016-11-29 2023-10-01 Regeneron Pharma Anti-human prolactin receptor (prlr) antibody-drug conjugates and use thereof in combination therapy of prlr positive breast cancer
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2018179138A1 (ja) * 2017-03-29 2018-10-04 持田製薬株式会社 抗体含有液体製剤
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
WO2018191414A1 (en) 2017-04-11 2018-10-18 Kiniksa Pharmaceuticals, Ltd. Stable anti-osmr antibody formulation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
US12168054B2 (en) 2017-05-19 2024-12-17 Syndax Pharmaceuticals, Inc. Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
PE20200481A1 (es) 2017-07-10 2020-03-03 Bayer Pharma AG Anticuerpo del receptor de prolactina para la perdida de cabello con patrones masculinos y femeninos
EP3713591A1 (en) 2017-11-20 2020-09-30 Just-Evotec Biologics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
SG11202007363TA (en) 2018-02-07 2020-08-28 Regeneron Pharma Methods and compositions for therapeutic protein delivery
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
JP7475335B2 (ja) * 2018-09-13 2024-04-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｓｆ－１ｒ抗体製剤
MY209127A (en) * 2018-10-18 2025-06-23 Merck Sharp & Dohme Llc Formulations of anti-rsv antibodies and methods of use thereof
EP4306128A3 (en) * 2018-10-30 2024-03-27 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
JOP20210229A1 (ar) 2019-02-18 2023-01-30 Lilly Co Eli صيغة جسم مضاد علاجي
TW202519263A (zh) * 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
WO2021262329A1 (en) * 2020-06-24 2021-12-30 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2025518049A (ja) * 2022-05-26 2025-06-12 コンピュジェン リミテッド 抗ｔｉｇｉｔ抗体製剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
US7867493B2 (en) * 2006-08-18 2011-01-11 Novartis Ag PRLR-specific antibody and uses thereof
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
CA2477857C (en) 1999-10-04 2012-04-10 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
SG165158A1 (en) 2002-05-02 2010-10-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
JP4648002B2 (ja) 2002-06-21 2011-03-09 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの安定化された固体組成物
CN1751236A (zh) * 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
HUE051878T2 (hu) 2003-02-10 2021-03-29 Biogen Ma Inc Immunglobulin készítmény és annak elõállítási módszere
AU2004222625A1 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
CN1761747A (zh) 2003-03-18 2006-04-19 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
MX369959B (es) 2003-05-14 2019-11-27 Immunogen Inc Composicion de farmaco conjugado.
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
DE602004025100D1 (de) 2003-05-23 2010-03-04 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
EP1644030B1 (en) 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
DE10361599A1 (de) 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Flüssigformulierung von Antikörperkonjugaten
DE102004022927A1 (de) 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
WO2006014965A2 (en) 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Ｆｇｆ−２０の調合物、生成方法および使用
DE102005002353A1 (de) * 2005-01-18 2006-07-27 Abbott Gmbh & Co. Kg AGER-Rezeptor Multimerisierungs Epitope
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
WO2007002543A2 (en) * 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
ES2390354T3 (es) 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
BRPI0707796A2 (pt) 2006-02-15 2011-05-10 Imclone Systems Inc formulaÇço, e, mÉtodo de tratamento
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2008039761A2 (en) 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
WO2008081024A1 (en) 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
MX2009011408A (es) 2007-05-02 2009-11-05 Hoffmann La Roche Metodo para estabilizar una proteina.
US20100189721A1 (en) 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
AU2008289225A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and Fc-fusion molecules using polycations
ES2750254T3 (es) 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TW200938221A (en) 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
CN101951950A (zh) * 2007-12-21 2011-01-19 葛兰素史密丝克莱恩生物有限公司 疫苗
AU2008340429C1 (en) * 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP2011510043A (ja) 2008-01-23 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 新規血液凝固因子インヒビター
AR074357A1 (es) 2008-11-17 2011-01-12 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN104490767A (zh) * 2009-05-04 2015-04-08 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
NZ609557A (en) * 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
US7867493B2 (en) * 2006-08-18 2011-01-11 Novartis Ag PRLR-specific antibody and uses thereof
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions

Also Published As

Publication number Publication date
BR112015004397B1 (pt) 2022-07-19
CN111202843A (zh) 2020-05-29
SI2890397T1 (sl) 2019-11-29
PL2890397T3 (pl) 2019-12-31
TWI641384B (zh) 2018-11-21
ZA201501279B (en) 2016-11-30
MX2015002412A (es) 2015-09-29
UY34994A (es) 2014-03-31
TW201821103A (zh) 2018-06-16
RU2015111319A (ru) 2016-10-20
HRP20191199T1 (hr) 2019-10-18
JP2015528465A (ja) 2015-09-28
US20150252116A1 (en) 2015-09-10
IN2015DN02255A (cg-RX-API-DMAC7.html) 2015-08-21
CY1121990T1 (el) 2020-10-14
MX367691B (es) 2019-09-02
TW201422235A (zh) 2014-06-16
ES2742868T3 (es) 2020-02-17
TW201414491A (zh) 2014-04-16
IL237277B (en) 2020-04-30
US20140065158A1 (en) 2014-03-06
IL237277A0 (en) 2015-04-30
CN104736175B (zh) 2019-11-01
US20170008965A1 (en) 2017-01-12
US20150093393A1 (en) 2015-04-02
HK1207316A1 (en) 2016-01-29
CN104736175A (zh) 2015-06-24
JP6444871B2 (ja) 2018-12-26
AR092401A1 (es) 2015-04-22
SG11201501225SA (en) 2015-03-30
UY34999A (es) 2014-03-31
RU2649372C2 (ru) 2018-04-02
EP2890397B1 (en) 2019-06-19
HUE045494T2 (hu) 2019-12-30
PT2890397T (pt) 2019-09-10
TWI688404B (zh) 2020-03-21
CN111202844A (zh) 2020-05-29
DK2890397T3 (da) 2019-08-05
EP2890397A1 (en) 2015-07-08
US8883979B2 (en) 2014-11-11
CA2883097C (en) 2022-11-15
BR112015004397A2 (pt) 2017-12-19
LT2890397T (lt) 2019-09-25
NZ705178A (en) 2018-06-29
CA2883097A1 (en) 2014-03-06
AR092387A1 (es) 2015-04-22
KR20150046298A (ko) 2015-04-29
RS59207B1 (sr) 2019-10-31
KR102100282B1 (ko) 2020-04-13
AU2013308907A1 (en) 2015-03-12
WO2014036076A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
AU2013308907B2 (en) Anti-prolactin receptor antibody formulations
US9023357B2 (en) Anti-prolactin receptor antibody formulations
CA2665567C (en) Stable formulations
EP3652205A1 (en) Prolactin receptor antibody for male and female pattern hair loss
HK40020981A (en) Anti-prolactin receptor antibody formulations
HK40020980A (en) Anti-prolactin receptor antibody formulations
HK1207316B (zh) 抗催乳素受体抗体制剂
TW202237185A (zh) Ｈｅｒ２／ｎｅｕ抗體的藥物組合物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)